]>
IRCT20190706044121N1 IRCT 2020-01-10 Gorgan University of Medical Sciences Comparative study of Bupropion and Citalopram in response rate for patients with Major Depressive Disorder Comparative study of Bupropion and Citalopram in response rate for patients with Major Depressive Disorder 2020-01-11 anticipated 104 Complete https://irct.ir/trial/40631 interventional Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Participants in the study were randomly assigned into two groups of intervention (A) and (B). In this way, the cases will be randomly assigned to one of two study groups with the help of random number table and receive the intervention of the same group. 3 Major Depressive Disorder. Intervention 1: Intervention group: Bupropion (Welban company) with the starter dose of 75 mg/day and maximum dose of 300 mg daily for at least 4 weeks. Intervention 2: Control group: Citalopram Pharmaceutical company Abidi The starting dose of 20 mg daily and a maximum dose of 40 mg daily for at least 4 weeks. Yes - There is a plan to make this available What will be shared: Only part of the data that is listed in the variables table will be shared without name and in general results. When: Start of access period 6 months after printing results To whom: Only for researchers working in academic and academic institutions Conditions: For use in meta-analysis and systematic review articles Where to obtain: Dr mitra Joodi psychiatry department, 5 th Azar hospital, 5 th Azar Ave, Gorgan drmitrajioodi@goums.ac.ir How to obtain: After receiving the request by email or postal address, the researcher will check the request for 10 working days and if the item is usable in professional cases, the data will be provided to the applicant. Comments:
public Dr Mitra Joodi Mashhad
Psychiatry Department, 5 th Azar Hospital, 5 th Azar Ave
Gorgan Iran (Islamic Republic of) 4917761551 +98 17 3222 0561 drmitrajioodi@goums.ac.ir Gorgan University of Medical Sciences scientific Dr Mitra Joodi Mashhad
Psychiatry Department, 5 th Azar Hospital, 5 th Azar Ave
Gorgan Iran (Islamic Republic of) 4917761551 +98 17 3222 0561 drmitrajioodi@goums.ac.ir Gorgan University of Medical Sciences Iran (Islamic Republic of) Diagnosis of major depressive disorder based on structured clinical interview and DSM-5 Older than 30 years old Sufficient fluency in Farsi and literacy reading and writing lack of any comorbid disorder, especially anxiety disorders and substance use retarded or normal psychomotor 30 years no limit Both previous appropriate response to a certain antidepressants taking antidepressants when visiting using BZDs, mood stablizers or antipsychotics concurrent psychotherapy medical conditions including cardiovascular disease suicidal ideations and psychotic symptoms need to admit to the mental ward agitation or mixed mood symptoms F32 Major depressive disorder, single episode Treatment - Drugs Treatment - Drugs Intervention group: Bupropion (Welban company) with the starter dose of 75 mg/day and maximum dose of 300 mg daily for at least 4 weeks Control group: Citalopram Pharmaceutical company Abidi The starting dose of 20 mg daily and a maximum dose of 40 mg daily for at least 4 weeks Objective treatment response. Timepoint: at baseline and 2 and 4 weeks after pharmacotherapy. Method of measurement: Reduction of more than 50% of base score on Hamilton Depression Rating Scale (HAM-D). Subjective treatment response. Timepoint: at baseline and after 2 and 4 weeks of pharmacotherapy. Method of measurement: reduction of baseline score in Cognitive Triad Inventory (TCI). Gorgan University of Medical Sciences Approved 2019-09-08 Ethics Committee of Golestan University of Medical Sciences Central organization of Golestan University of Medical Sciences, Hirkan Drive Gorgan Golestan Iran (Islamic Republic of)